$2.91
15.94% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
KYG108301006
Symbol
BYSI
Sector
Industry

BeyondSpring Inc. Stock price

$2.91
+1.26 76.36% 1M
+1.36 87.50% 6M
+1.28 78.53% YTD
+0.55 23.31% 1Y
-13.47 82.23% 5Y
-13.89 82.68% 10Y
-13.89 82.68% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
+0.40 15.94%
ISIN
KYG108301006
Symbol
BYSI
Sector
Industry

Key metrics

Market capitalization $117.32m
Enterprise Value $108.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 108.79
P/S ratio (TTM) P/S ratio 117.32
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $1.00m
EBIT (operating result TTM) EBIT $-18.79m
Free Cash Flow (TTM) Free Cash Flow $-4.25m
Cash position $8.53m
EPS (TTM) EPS $-0.34
Short interest 6.46%
Show more

Is BeyondSpring Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

BeyondSpring Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BeyondSpring Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast BeyondSpring Inc.:

Buy
100%

Financial data from BeyondSpring Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1 1
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
-
1,212%
- Research and Development Expense 7.67 7.67
-
767%
-19 -19
-
-1,871%
- Depreciation and Amortization 0.08 0.08
-
8%
EBIT (Operating Income) EBIT -19 -19
-
-1,879%
Net Profit -14 -14
-
-1,391%

In millions USD.

Don't miss a Thing! We will send you all news about BeyondSpring Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BeyondSpring Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer (NSCLC) after disease progression on 1L PD-1/L1 inhibitors with and ...
Neutral
GlobeNewsWire
about one month ago
FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical‑stage global biopharmaceutical company focused on developing cancer therapeutics, today announced its unaudited financial results for the quarter ended March 31, 2025, and provided a corporate update.
Neutral
GlobeNewsWire
3 months ago
FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”) on March 27, 2025....
More BeyondSpring Inc. News

Company Profile

BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.

Head office Cayman Islands
CEO Lan Huang
Employees 40
Founded 2010
Website www.beyondspringpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today